following convention: very common (≥10%); common (≥1% to <10%), uncommon (≥0.1% to <1%) or rare (≥0.01% to <0.1%). More Common Clinical Adverse Drug Reactions (≥1%) not reported in the controlled period. Blood and Lymphatic System Disorders Leucopenia. Common: General Disorders and Administration Site Conditions Fatigue. Common: Infections and Infestations Pneumonia, sinusitis, pharyngitis. Common: Investigations Hepatic enzyme increased, blood cholesterol increased Common: Metabolism and Nutrition Disorders Hyperlipidemia, dyslipidemia. Common: Musculoskeletal and Connective Tissue Disorders Musculoskeletal pain. Common: Psychiatric Disorders Insomnia. Common: Respiratory, Thoracic and Mediastinal Disorders Dyspnoea Common: Skin and Subcutaneous Tissue Disorders Rash. Common: Less Common Clinical Adverse Drug Reactions (<1%) Blood and Lymphatic System Disorders Neutropenia, lymphopenia. Uncommon:
following convention: very common (≥10%); common (≥1% to <10%), uncommon (≥0.1% to <1%) or rare (≥0.01% to <0.1%). More Common Clinical Adverse Drug Reactions (≥1%) not reported in the controlled period. Blood and Lymphatic System Disorders Common: Leucopenia. General Disorders and Administration Site Conditions Common: Fatigue. Infections and Infestations Common: Pneumonia, sinusitis, pharyngitis. Investigations Common: Hepatic enzyme increased, blood cholesterol increased Metabolism and Nutrition Disorders Common: Hyperlipidemia, dyslipidemia. Musculoskeletal and Connective Tissue Disorders Common: Musculoskeletal pain. Psychiatric Disorders Common: Insomnia. Respiratory, Thoracic and Mediastinal Disorders Common: Dyspnoea Skin and Subcutaneous Tissue Disorders Common: Rash. Less Common Clinical Adverse Drug Reactions (<1%) Blood and Lymphatic System Disorders Uncommon: Neutropenia, lymphopenia.
auspar-tofacitinib-as-citrate-180525-pi.docx